Novel treatment for bone marrow cancer
Multiple myeloma is a form of cancer in which the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anaemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, can often be an important treatment option for many patients. Unfortunately, multiple myeloma continues to progress even after a transplant. Within this domain, European researchers have been looking into alternative treatment and in particular at marine extracts and active substances in their search for new methods to fight this disease.
The ocean has proved to be an interesting environment for researchers who are already mining our seas for news drugs. Oceans are also home to other treasures able to inspire researchers worldwide. However, there is fierce competition in the ocean habitat, and to survive there marine organisms use an entire arsenal of chemical weapons to defend themselves against their rivals. With the help of these chemicals they can attack hostile cells by overcoming their defence system. Researchers have discovered that these organisms produce an interesting active substance that could be a great candidate for use in cancer research. Indeed, natural marine-based substances have been found to penetrate a tumour's protective shield. The EU-funded OPTATIO project takes its inspiration from marine organisms and in particular the active substance they produce.
Two-thirds of cases of multiple myeloma develop in older patients (average age at diagnosis is 69 years) and the cancer is nearly always incurable. This immune system tumour develops from mature antibodies which produce B cells. It begins as a single degenerative cell which multiplies on a massive scale and infiltrates the bone marrow and beyond.
Multiple myeloma cells grow in niches in the bone marrow. They are surrounded by tissue cells, bone marrow cells (osteoblasts and osteoclasts), blood vessel cells and immune cells. These cells stimulate each other in a highly interactive way, and there is regular interplay and exchange of messenger substances, e.g. cytokines. Genes are activated so that even more cytokines are produced to create a self-strengthening cycle. This helps the cancer cells to 'hide' and avoid cell death which normally results from medication. One of OPTATIO's main aims is to explain this resistance mechanism.
Until now, research on multiple myeloma cancer cells has often considered them as isolated entities. However, this tends to disregard the fact that the bone marrow environment, in particular the stromal bone tissue, the immune cells and the connective tissue cells, protects cancer cells with the aid of different substances in a so-called niche. In this biochemical 'shelter', drugs are often not effective in patients although they may have been successful in laboratory tests on isolated cancer cells. They have been found to be ineffective in the long term because the cancer cells become resistant.
OPTATIO is pursuing a unique strategy to break through this protective shield to enable better cancer treatment. In so doing, marine-based active substances are proving to be particularly attractive candidates as through evolution they have proven their capacity to survive in the chemical battles against marine organisms.
Oncotyrol, one of the consortium partners, has developed test systems comprising cancer as well as connective tissue cells to better replicate the actual conditions in the human body. Scientists from Prof. Lukas Huber's team have recently used 'in-vivo-like assays' to test hundreds of marine extracts as well as pure substances produced by Spanish biopharmaceutical company PharmaMar, another consortium partner. Of most importance in the screening process was the fact that the candidates kill the cancer cells while leaving the niche cells intact, according to Winfried Wunderlich of Oncotyrol. "We are looking for substances which disable the protective influence of the stroma on the cancer cells but do not destroy the connective tissue cells themselves," explained Mr Wunderlich to members of an international consortium. Thus, researchers have made good progress in achieving promising screening results. Indeed, the results revealed that a considerable part of the examined extracts and pure substances selectively affect the tumour cells, that is to say they broke through the protective shield.
The aim of the project is to exploit the importance of interactions between multiple myeloma cells and the bone marrow micro-environment. These interactions play a vital role in the survival of tumour cells, the development of drug resistance and the progression of the disease. Principally, OPTATIO will develop new and innovative multiple myeloma treatment strategies by targeting not only the 'seed', but also the 'soil' of myelomagenesis, searching for compounds that have the capacity to interfere with this complex biological network.
The project team's next step is to make their test systems even more realistic and investigate the promising candidates in further co-culture and animal models, in co-operation with other partners, including the University of Würzburg.
More information: OPTATIO: www.optatio.eu/abo… -us/profile/
Provided by CORDIS
- Stem cells make bone marrow cancer resistant to treatment Jan 11, 2008 | not rated yet | 0
- Possible new therapy for the treatment of myeloma Sep 05, 2012 | not rated yet | 0
- Researchers harness the immune system to improve stem cell transplant outcomes Oct 01, 2012 | not rated yet | 0
- Study shows benefit of new maintenance therapy for multiple myeloma May 11, 2012 | not rated yet | 0
- Towards more effective treatment for multiple myeloma Jan 09, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be villous adenoma in colon, if there are no villi there
11 hours ago As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
- More from Physics Forums - Medical Sciences
More news stories
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 1 hour ago | not rated yet | 0
National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...
Cancer 2 hours ago | not rated yet | 0
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Cancer 5 hours ago | not rated yet | 0 |
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...
Cancer 5 hours ago | not rated yet | 0 |
Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.
Cancer 9 hours ago | not rated yet | 0
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
57 minutes ago | not rated yet | 0
Calorie information in fast food restaurants used by 40 percent of 9-18 year olds when making food choices
A new study published online today (Thursday) in the Journal of Public Health has found that of young people who visited fast food or chain restaurants in the U.S. in 2010, girls and youth who were obese were more likely ...
2 minutes ago | not rated yet | 0
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
2 hours ago | 5 / 5 (1) | 0 |
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
1 hour ago | not rated yet | 0
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
3 hours ago | not rated yet | 1 |